Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xu Chao

Showing results (191-200 of 281) with videos related to

Pageof 29
Sort By:
Plos One|July 7, 2012
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking statusShe-Juan An, Zhi-Hong Chen, Jian Su, et al.
Lung Cancer (Amsterdam, Netherlands)|September 23, 2015
Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancersWen-zhao Zhong, Jian Su, Fang-ping Xu, et al.
Clinical Lung Cancer|December 15, 2020
Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901)Xiang-Meng Li, Wen-Feng Li, Jun-Tao Lin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung AdenocarcinomaChao Zhang, Jianjun Zhang, Fang-Ping Xu, et al.
Signal Transduction and Targeted Therapy|May 14, 2023
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancerJi Zhou, Xu-Chao Zhang, Shan Xue, et al.
Journal of Pharmaceutical Analysis|July 25, 2025
Aldolase A accelerates hepatocarcinogenesis by refactoring c-Jun transcriptionXin Yang, Guang-Yuan Ma, Xiao-Qiang Li, et al.
BMC Cancer|November 28, 2018
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpressionRui-Lian Chen, Jun Zhao, Xu-Chao Zhang, et al.
Thoracic Cancer|May 21, 2022
An integrated biomarker of PD-L1 expression and intraepithelial CD8<sup>+</sup> T cell infiltration was associated with the prognosis of lung cancer patients after intracranial resection of brain metastasesLin-Lin Li, De-Xiang Zhou, Ming Lu, et al.
The Oncologist|June 8, 2012
EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomasZhi-Yong Chen, Wen-Zhao Zhong, Xu-Chao Zhang, et al.
Therapeutic Advances in Medical Oncology|April 28, 2023
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patientsZhen Wang, Xu-Chao Zhang, Wei-Neng Feng, et al.
Pageof 29

Showing results (191-200 of 281) with videos related to

Sort By:
Pageof 29
Plos One|July 7, 2012
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking statusShe-Juan An, Zhi-Hong Chen, Jian Su, et al.
Lung Cancer (Amsterdam, Netherlands)|September 23, 2015
Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancersWen-zhao Zhong, Jian Su, Fang-ping Xu, et al.
Clinical Lung Cancer|December 15, 2020
Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901)Xiang-Meng Li, Wen-Feng Li, Jun-Tao Lin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung AdenocarcinomaChao Zhang, Jianjun Zhang, Fang-Ping Xu, et al.
Signal Transduction and Targeted Therapy|May 14, 2023
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancerJi Zhou, Xu-Chao Zhang, Shan Xue, et al.
Journal of Pharmaceutical Analysis|July 25, 2025
Aldolase A accelerates hepatocarcinogenesis by refactoring c-Jun transcriptionXin Yang, Guang-Yuan Ma, Xiao-Qiang Li, et al.
BMC Cancer|November 28, 2018
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpressionRui-Lian Chen, Jun Zhao, Xu-Chao Zhang, et al.
Thoracic Cancer|May 21, 2022
An integrated biomarker of PD-L1 expression and intraepithelial CD8<sup>+</sup> T cell infiltration was associated with the prognosis of lung cancer patients after intracranial resection of brain metastasesLin-Lin Li, De-Xiang Zhou, Ming Lu, et al.
The Oncologist|June 8, 2012
EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomasZhi-Yong Chen, Wen-Zhao Zhong, Xu-Chao Zhang, et al.
Therapeutic Advances in Medical Oncology|April 28, 2023
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patientsZhen Wang, Xu-Chao Zhang, Wei-Neng Feng, et al.
Pageof 29